期刊
BIOCONJUGATE CHEMISTRY
卷 26, 期 11, 页码 2170-2175出版社
AMER CHEMICAL SOC
DOI: 10.1021/acs.bioconjchem.5b00173
关键词
-
类别
资金
- National Cancer Institute, National Institutes of Health [BRL OOTC PID 001.015.0002.0001]
The therapeutic cargo molecules conjugated to a specific site on a monoclonal antibody (mAb), called antibody drug conjugates (ADCs), are becoming powerful tools in cancer treatment. Generally, the cargo molecules conjugate at the cysteine or lysine residue of the mAb, which generally results in a highly heterogeneous ADC. Therapeutic cargo molecules need to be conjugated in a site-specific manner to the mAb so that the bioefficacy of these molecules is not compromised. The mAb (IgG1) are N-glycosylated at the conserved residue Asn(297), which is present in each heavy chain of the IgG1, near the CH2 domain of the Fc fragment. The mutant or wild-type glycosyltransferases transfer sugars with a chemical handle to the glycan molecule of IgG1, making the site-specific linking of cargo molecules possible via the chemical handle, and thus making the process an invaluable technique for the production of homogeneous ADCs.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据